Public Sector Pension Investment Board increased its stake in Abbott Laboratories (NYSE:ABT – Free Report) by 32.7% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 1,821,369 shares of the healthcare product maker’s stock after buying an additional 448,744 shares during the quarter. Public Sector Pension Investment Board’s holdings in Abbott Laboratories were worth $187,838,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. BlackRock Inc. raised its stake in Abbott Laboratories by 4.6% during the second quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker’s stock valued at $13,843,610,000 after buying an additional 6,769,518 shares during the last quarter. State Street Corp boosted its holdings in Abbott Laboratories by 1.7% in the second quarter. State Street Corp now owns 80,926,234 shares of the healthcare product maker’s stock worth $7,343,246,000 after acquiring an additional 1,350,766 shares in the last quarter. Bank of America Corp DE purchased a new stake in shares of Abbott Laboratories in the second quarter worth $1,603,607,000. Deutsche Bank AG grew its stake in shares of Abbott Laboratories by 18.6% in the second quarter. Deutsche Bank AG now owns 16,706,669 shares of the healthcare product maker’s stock worth $1,515,963,000 after acquiring an additional 2,614,965 shares during the last quarter. Finally, Legal & General Group Plc purchased a new stake in shares of Abbott Laboratories in the second quarter worth $1,082,524,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.
Abbott Laboratories Stock Performance
ABT stock opened at $104.64 on Wednesday. The stock’s 50 day simple moving average is $103.89 and its 200 day simple moving average is $101.74. The company has a current ratio of 1.45, a quick ratio of 1.00 and a debt-to-equity ratio of 0.57. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $132.02. The stock has a market capitalization of $181.23 billion, a PE ratio of 39.04, a price-to-earnings-growth ratio of 1.88 and a beta of 0.54.
Abbott Laboratories Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Monday, November 16th. Investors of record on Thursday, October 15th were given a dividend of $0.63 per share. The ex-dividend date of this dividend was Thursday, October 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.4%. Abbott Laboratories’s dividend payout ratio (DPR) is 94.03%.
Wall Street Analysts Forecast Growth
Several equities analysts have recently weighed in on the company. JPMorgan Chase & Co. reduced their price target on Abbott Laboratories from $120.00 to $118.00 and set an “overweight” rating for the company in a report on Thursday, October 22nd. Royal Bank Of Canada dropped their price target on shares of Abbott Laboratories from $130.00 to $125.00 and set an “outperform” rating on the stock in a research note on Thursday, October 22nd. Wall Street Zen raised shares of Abbott Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, October 24th. Citigroup reduced their price objective on shares of Abbott Laboratories from $125.00 to $122.00 and set a “buy” rating for the company in a research note on Thursday, October 22nd. Finally, TD Cowen decreased their target price on shares of Abbott Laboratories from $135.00 to $118.00 and set a “buy” rating for the company in a report on Thursday, October 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $118.32.
Check Out Our Latest Research Report on Abbott Laboratories
Insider Activity at Abbott Laboratories
In related news, EVP Mary Moreland sold 3,500 shares of Abbott Laboratories stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $116.00, for a total value of $406,000.00. Following the completion of the sale, the executive vice president directly owned 100,791 shares in the company, valued at approximately $11,691,756. This trade represents a 3.36% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.46% of the stock is owned by company insiders.
Abbott Laboratories Company Profile
Abbott Laboratories is a global healthcare company that develops, manufactures and markets medical devices, diagnostic tests, nutritional products and branded generic medicines. Its products serve patients and healthcare professionals in hospitals, clinics and other care settings. Abbott’s offerings include the FreeStyle Libre continuous glucose monitoring system, cardiovascular and other medical devices, laboratory and rapid diagnostic tests, and nutrition brands such as Ensure and Similac. Its established pharmaceuticals business sells branded generic medicines in markets outside the United States.
Read More
- Five stocks we like better than Abbott Laboratories
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
